{"id":"ursodeoxycholic-acid-urso","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Diarrhea"},{"rate":"5-15","effect":"Abdominal discomfort"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_dailymed":{"setId":"9f892c0a-8cab-4515-8074-fbfaa1781946","title":"URSODEOXYCHOLIC ACID (URSODIOL) POWDER [BLUEBAY SHANDONG CO.,LTD]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"URSO decreases cholesterol absorption and secretion into bile, reducing cholestasis and hepatic injury. It also has immunomodulatory properties that may protect against bile acid-induced cellular damage and reduce inflammation in biliary and hepatic tissues. These mechanisms make it useful in cholestatic liver diseases and as a hepatoprotective agent.","oneSentence":"Ursodeoxycholic acid is a bile acid that reduces cholesterol saturation in bile and promotes its solubilization, while also exerting cytoprotective and anti-inflammatory effects on hepatocytes and biliary epithelium.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:07:04.759Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary biliary cholangitis (PBC)"},{"name":"Primary sclerosing cholangitis (PSC)"},{"name":"Gallstone dissolution"},{"name":"Cholestasis and liver protection in various hepatic conditions"}]},"trialDetails":[{"nctId":"NCT06517862","phase":"PHASE4","title":"Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia","status":"RECRUITING","sponsor":"Amira Adel Fouly","startDate":"2024-09-01","conditions":"Neonatal Hyperbilirubinemia","enrollment":80},{"nctId":"NCT07477782","phase":"PHASE2","title":"Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05","conditions":"Primary Sclerosing Cholangitis (PSC), Inflammatory Bowel Disease (IBD)","enrollment":72},{"nctId":"NCT03431896","phase":"","title":"Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2018-02-01","conditions":"Amyloidosis, Amyloid, Amyloid Neuropathies, Familial","enrollment":37},{"nctId":"NCT03724175","phase":"PHASE2, PHASE3","title":"The Role of Secondary Bile Acids in Intestinal Inflammation","status":"TERMINATED","sponsor":"Stanford University","startDate":"2019-08-26","conditions":"Ulcerative Colitis, Pouchitis","enrollment":2},{"nctId":"NCT07457632","phase":"PHASE2","title":"Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Combining Tauroursodeoxycholate and Traditional Chinese Medicine.","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Diabetic Macular Edema (DME)","enrollment":69},{"nctId":"NCT06383403","phase":"PHASE3","title":"A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2024-07-09","conditions":"Primary Biliary Cholangitis","enrollment":69},{"nctId":"NCT04526665","phase":"PHASE3","title":"Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2020-09-24","conditions":"Primary Biliary Cirrhosis","enrollment":161},{"nctId":"NCT07424677","phase":"PHASE3","title":"Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy","status":"NOT_YET_RECRUITING","sponsor":"Zydus Therapeutics Inc.","startDate":"2026-03","conditions":"Primary Biliary Cholangitis","enrollment":89},{"nctId":"NCT07378761","phase":"PHASE2","title":"Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2026-02","conditions":"Immune-Mediated Cholestasis","enrollment":94},{"nctId":"NCT06755151","phase":"PHASE3","title":"Fenofibrate in Primary Biliary Cholangitis: a Real World Study","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-01-17","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":300},{"nctId":"NCT05751967","phase":"PHASE3","title":"Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-02-22","conditions":"Primary Biliary Cholangitis","enrollment":150},{"nctId":"NCT06174402","phase":"PHASE2, PHASE3","title":"Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Ying","startDate":"2023-08-21","conditions":"Primary Biliary Cholangitis","enrollment":184},{"nctId":"NCT06755541","phase":"PHASE3","title":"Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-01-30","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":150},{"nctId":"NCT05749822","phase":"PHASE2, PHASE3","title":"Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-02-17","conditions":"Primary Biliary Cholangitis","enrollment":104},{"nctId":"NCT00200343","phase":"PHASE3","title":"Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2002-07","conditions":"Chronic Hepatitis C","enrollment":596},{"nctId":"NCT06415773","phase":"PHASE3","title":"Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"HighTide Biopharma Pty Ltd","startDate":"2024-06-04","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":367},{"nctId":"NCT07282353","phase":"PHASE3","title":"A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA","status":"RECRUITING","sponsor":"Cascade Pharmaceuticals, Inc","startDate":"2025-12-01","conditions":"Primary Biliary Cholangitis","enrollment":135},{"nctId":"NCT06350890","phase":"PHASE3","title":"Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"HighTide Biopharma Pty Ltd","startDate":"2023-11-05","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":408},{"nctId":"NCT07296458","phase":"PHASE3","title":"FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2025-12-15","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":132},{"nctId":"NCT06091787","phase":"NA","title":"Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration on Right Lobe Donor Hepatectomy","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-09-01","conditions":"Liver Regeneration, Ursodeoxycholic Acid, Partial Liver Resection","enrollment":90},{"nctId":"NCT06922669","phase":"NA","title":"Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-06-24","conditions":"Drug Induced Liver Injury","enrollment":232},{"nctId":"NCT07273734","phase":"NA","title":"UDCA to Prevent Post-TIPS Hepatic Encephalopathy","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-01-01","conditions":"Hepatic Encephalopathy (HE), TIPS","enrollment":270},{"nctId":"NCT07110987","phase":"NA","title":"The Efficacy of Ursodeoxycholic Acid (UDCA) as Adjuvant Therapy to Phototherapy in the Management of Neonatal Indirect Hyperbilirubinemia","status":"RECRUITING","sponsor":"Tishreen University Hospital","startDate":"2025-06-26","conditions":"Hyperbilirubinemia, Neonatal Indirect","enrollment":70},{"nctId":"NCT06610760","phase":"PHASE4","title":"Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia","status":"RECRUITING","sponsor":"Yongquan Shi","startDate":"2024-11-12","conditions":"Gastric Intestinal Metaplasia","enrollment":196},{"nctId":"NCT06591468","phase":"PHASE2, PHASE3","title":"A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics","status":"ENROLLING_BY_INVITATION","sponsor":"Han Ying","startDate":"2024-10-30","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":244},{"nctId":"NCT06591455","phase":"EARLY_PHASE1","title":"A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis","status":"COMPLETED","sponsor":"Han Ying","startDate":"2024-09-14","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":30},{"nctId":"NCT06353347","phase":"PHASE3","title":"Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"HighTide Biopharma Pty Ltd","startDate":"2023-11-13","conditions":"Type 2 Diabetes Mellitus","enrollment":551},{"nctId":"NCT04594694","phase":"PHASE2","title":"Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC","status":"TERMINATED","sponsor":"Intercept Pharmaceuticals","startDate":"2019-10-02","conditions":"Primary Biliary Cholangitis","enrollment":75},{"nctId":"NCT06488911","phase":"PHASE3","title":"To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate","status":"TERMINATED","sponsor":"Intercept Pharmaceuticals","startDate":"2024-07-01","conditions":"Primary Biliary Cholangitis","enrollment":63},{"nctId":"NCT06884748","phase":"EARLY_PHASE1","title":"Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-12-01","conditions":"Clostridioides Difficile Infection","enrollment":30},{"nctId":"NCT07005752","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones).","status":"RECRUITING","sponsor":"Myungmoon Pharma. Co. Ltd.","startDate":"2025-07-28","conditions":"Cholesterol Cholelithiasis","enrollment":484},{"nctId":"NCT06684106","phase":"NA","title":"Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance","status":"RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2024-11-25","conditions":"Hyperlipidemia, Ursodeoxycholic Acid, Statin Therapy","enrollment":128},{"nctId":"NCT06247735","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kowa Research Institute, Inc.","startDate":"2024-02-07","conditions":"Primary Biliary Cholangitis","enrollment":46},{"nctId":"NCT06443606","phase":"PHASE3","title":"Efficacy and Safety of Bezafibrate 400 mg and Bezafibrate 200 mg as Adjunctive Treatments in Patients With Primary Biliary Cholangitis and Non-optimal Biochemical Response to Ursodeoxycholic Acid Therapy","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-03-27","conditions":"BPC, Non Optimal Response to UDCA","enrollment":108},{"nctId":"NCT07122206","phase":"","title":"Monitoring the Response of Combination Ursodiol and Seladelpar Treatment","status":"NOT_YET_RECRUITING","sponsor":"Methodist Health System","startDate":"2025-08","conditions":"Primary Biliary Cholangitis","enrollment":100},{"nctId":"NCT07102979","phase":"NA","title":"Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response","status":"ENROLLING_BY_INVITATION","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-09-01","conditions":"Liver Cirrhosis","enrollment":150},{"nctId":"NCT07068191","phase":"NA","title":"Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly","status":"RECRUITING","sponsor":"Phenomen Pharma","startDate":"2025-06-19","conditions":"Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL)","enrollment":90},{"nctId":"NCT07072949","phase":"PHASE1","title":"The Impact of Ursodeoxycholic Acid and Probiotics on Metabolic Outcomes in Type 2 Diabetic Patients Taking Metformin","status":"COMPLETED","sponsor":"University of Banja Luka","startDate":"2023-01-03","conditions":"Type 2 Diabetes Mellitus","enrollment":90},{"nctId":"NCT06365424","phase":"PHASE2, PHASE3","title":"Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2017-04-08","conditions":"Primary Biliary Cholangitis","enrollment":117},{"nctId":"NCT00873275","phase":"PHASE1","title":"Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2009-03-11","conditions":"Colorectal Cancer","enrollment":11},{"nctId":"NCT06294847","phase":"PHASE3","title":"Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery","status":"RECRUITING","sponsor":"Hopital Foch","startDate":"2024-08-20","conditions":"Retinal Detachment","enrollment":120},{"nctId":"NCT06060665","phase":"PHASE3","title":"Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-09-05","conditions":"Primary Biliary Cholangitis","enrollment":90},{"nctId":"NCT02961413","phase":"","title":"A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）","status":"RECRUITING","sponsor":"Drug Induced Liver Disease Study Group","startDate":"2016-04","conditions":"Drug-induced Liver Injury","enrollment":10000},{"nctId":"NCT06864481","phase":"","title":"Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-04-22","conditions":"Liver Injury, Secondary to Immune Checkpoint Inhibitors, Cancer Patients","enrollment":250},{"nctId":"NCT04407650","phase":"PHASE4","title":"Ursodeoxycholic Acid vs Metformin in Gestational Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"King's College London","startDate":"2021-07-01","conditions":"Gestational Diabetes","enrollment":64},{"nctId":"NCT06918080","phase":"PHASE4","title":"Hepatoprotective Measures for Children at High Risk of NAFLD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","startDate":"2023-11-19","conditions":"Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight, Acute Lymphoblastic Leukemia","enrollment":200},{"nctId":"NCT06026865","phase":"NA","title":"S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2023-08-01","conditions":"Primary Sclerosing Cholangitis (PSC)","enrollment":60},{"nctId":"NCT04650243","phase":"PHASE4","title":"Clinical Research of Tapering UDCA in PBC Patients With a Complete Response","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2020-01-21","conditions":"Primary Biliary Cholangitis","enrollment":90},{"nctId":"NCT03188146","phase":"","title":"Performance of Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2017-05-01","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":57},{"nctId":"NCT04924868","phase":"PHASE3","title":"Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis","status":"RECRUITING","sponsor":"Hospital General Universitario de Alicante","startDate":"2021-11-10","conditions":"Acute Pancreatitis Due to Gallstones","enrollment":332},{"nctId":"NCT05256979","phase":"","title":"Ursodeoxycholic Acid in Patients With NAFLD - Clinical Observation","status":"ACTIVE_NOT_RECRUITING","sponsor":"General University Hospital, Prague","startDate":"2022-07-02","conditions":"Non-Alcoholic Fatty Liver Disease","enrollment":20},{"nctId":"NCT02609048","phase":"PHASE2","title":"Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-11-04","conditions":"Primary Biliary Cirrhosis (PBC)","enrollment":41},{"nctId":"NCT06842472","phase":"PHASE2","title":"PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-02","conditions":"Breast Cancer","enrollment":70},{"nctId":"NCT05659654","phase":"PHASE1, PHASE2","title":"The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-12-16","conditions":"COVID-19","enrollment":95},{"nctId":"NCT06715319","phase":"PHASE3","title":"Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis","status":"COMPLETED","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2021-10-09","conditions":"PBC","enrollment":100},{"nctId":"NCT05925309","phase":"NA","title":"Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2023-07-01","conditions":"Biliary Atresia, Cholangitis, Anti-Bacterial Agents","enrollment":356},{"nctId":"NCT06629909","phase":"PHASE1","title":"Safety and Feasibility of Human Umbilical Cord Mesenchymal Stem Cell-Derived Secretome in the Treatment of Liver Cirrhosis: a Comprehensive Evaluation of Fibrosis Reduction, Immunomodulation, and Hepatic Regeneration: a Single Center, Randomized, Phase I Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Baermed","startDate":"2024-12-01","conditions":"Liver Cirrhosis","enrollment":54},{"nctId":"NCT04620733","phase":"PHASE3","title":"RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2021-04-21","conditions":"Primary Biliary Cholangitis","enrollment":193},{"nctId":"NCT00909610","phase":"PHASE1","title":"Ursodiol Tablets 500 mg Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2006-12","conditions":"Healthy","enrollment":80},{"nctId":"NCT00909753","phase":"PHASE1","title":"Ursodiol 500 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2006-09","conditions":"Healthy","enrollment":92},{"nctId":"NCT03004118","phase":"PHASE4","title":"Therapeutic Effect of Ursodeoxycholic Acid in Functional Dyspepsia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2017-01","conditions":"Functional Dyspepsia","enrollment":16},{"nctId":"NCT05410535","phase":"PHASE4","title":"To Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gasterectomy","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-09-15","conditions":"Gastric Cancer","enrollment":431},{"nctId":"NCT06278090","phase":"","title":"Impact of Ursodeoxycholic Acid Treatment on the Gallbladder Polyp Evolution","status":"RECRUITING","sponsor":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","startDate":"2024-03-01","conditions":"Gallbladder Polyp","enrollment":36},{"nctId":"NCT05973370","phase":"PHASE2","title":"Evaluating the Effect of Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-05-01","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT06411275","phase":"PHASE2","title":"A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"HighTide Biopharma Pty Ltd","startDate":"2022-03-31","conditions":"Type 2 Diabetes Mellitus","enrollment":113},{"nctId":"NCT05526807","phase":"NA","title":"Ursodeoxycholic Acid in C. Difficile Infection","status":"TERMINATED","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2019-05-08","conditions":"Clostridioides Difficile Infection","enrollment":6},{"nctId":"NCT06309589","phase":"NA","title":"The Effectiveness of Combining Ursodeoxycholic Acid With Vitamin D in Treating Patients With Primary Biliary Cholangitis","status":"COMPLETED","sponsor":"Yilihamu·Abilitifu","startDate":"2021-05-01","conditions":"Primary Biliary Cholangitis","enrollment":60},{"nctId":"NCT06287931","phase":"NA","title":"Probiotics for Gallstones in Post-bariatric Surgery Patients","status":"UNKNOWN","sponsor":"Shandong Linglong Yingcheng Hospital","startDate":"2024-01-01","conditions":"Bariatric Surgery Candidate, Gallstone, Gallstone Attack","enrollment":400},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT03954327","phase":"PHASE2","title":"Combination Antiretroviral Therapy (cART) for PBC","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2021-03-01","conditions":"Primary Biliary Cholangitis","enrollment":37},{"nctId":"NCT00550862","phase":"PHASE2","title":"Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)","status":"TERMINATED","sponsor":"Intercept Pharmaceuticals","startDate":"2007-10","conditions":"Liver Cirrhosis, Biliary","enrollment":165},{"nctId":"NCT06127355","phase":"PHASE3","title":"Gestational Treatment With Ursodeoxycholic Acid Compared to Placebo to Reduce Severity of Gestational Diabetes Mellitus Diagnosed at 24-28 Weeks' Gestation","status":"COMPLETED","sponsor":"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","startDate":"2021-03-03","conditions":"Gestational Diabetes","enrollment":113},{"nctId":"NCT05904067","phase":"NA","title":"A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-06-10","conditions":"COVID-19, Hematopoietic Stem Cell Transplantation","enrollment":72},{"nctId":"NCT05902468","phase":"PHASE2, PHASE3","title":"Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-06-28","conditions":"Diabetes Mellitus, Type 2","enrollment":88},{"nctId":"NCT03602976","phase":"PHASE2","title":"Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis","status":"TERMINATED","sponsor":"Ethan Weinberg","startDate":"2018-08-20","conditions":"Hepatic Sarcoidosis, Elevated Alkaline Phosphatase","enrollment":7},{"nctId":"NCT04076527","phase":"","title":"Prospective, Multicenter Cohort Study on Primary Biliary Cholangitis","status":"UNKNOWN","sponsor":"University of Leipzig","startDate":"2019-09-19","conditions":"PBC, Primary Biliary Cholangitis","enrollment":1200},{"nctId":"NCT05416580","phase":"PHASE3","title":"Efficacy of Ursodeoxycholic Acid (UDCA) in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"University of Banja Luka","startDate":"2022-09-12","conditions":"Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT05849558","phase":"PHASE4","title":"Study to Compare the Efficacy & Safety of Ursoplus Capsules vs. UDCA vs. Placebo Among Chronic Liver Disease Patients","status":"UNKNOWN","sponsor":"MinaPharm Pharmaceuticals","startDate":"2022-02-22","conditions":"Chronic Liver Disease","enrollment":297},{"nctId":"NCT05832697","phase":"PHASE1","title":"An Exploratory Clinical Trial to Evaluate and Compare Safety and Pharmacokinetic Characteristics After Administration of the DWJ1439, DWJ1464, DWC202108 or DWC202109 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-01-27","conditions":"Healthy Subject","enrollment":44},{"nctId":"NCT05812612","phase":"","title":"UDCA in the Treatment of COVID-19 Infection and Its Clinical Prognosis in Patients With Autoimmune Liver Disease","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2023-01-30","conditions":"COVID-19 Infection","enrollment":2000},{"nctId":"NCT05690646","phase":"PHASE4","title":"Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-01-28","conditions":"Cardiac Surgery","enrollment":491},{"nctId":"NCT04834557","phase":"PHASE2","title":"Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2021-11-01","conditions":"Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT02823353","phase":"PHASE3","title":"Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2016-04-08","conditions":"Primary Biliary Cirrhosis","enrollment":117},{"nctId":"NCT01654731","phase":"PHASE3","title":"Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-10-15","conditions":"PBC","enrollment":100},{"nctId":"NCT04542473","phase":"PHASE2, PHASE3","title":"Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2021-07-01","conditions":"SEPSIS, MALNUTRITION, CHILD","enrollment":400},{"nctId":"NCT03266146","phase":"PHASE1, PHASE2","title":"36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent DILI","status":"COMPLETED","sponsor":"Beijing 302 Hospital","startDate":"2017-09-02","conditions":"Drug-induced Liver Injury,Chronic","enrollment":90},{"nctId":"NCT04531878","phase":"PHASE2, PHASE3","title":"BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2023-02-08","conditions":"Hereditary Diseases, Cholestasis, Intrahepatic","enrollment":""},{"nctId":"NCT05685888","phase":"","title":"Effect of Ursodeoxycholic Acid on Preventing Covid-19 Infection in Patients With Organ Transplantation","status":"COMPLETED","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2015-01-01","conditions":"Organ Transplantation, COVID-19","enrollment":2000},{"nctId":"NCT05467553","phase":"PHASE2","title":"A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2023-02-24","conditions":"Hepatitis D","enrollment":30},{"nctId":"NCT04910178","phase":"PHASE4","title":"Follow-up of NAFLD Patients With MRI-PDFF","status":"COMPLETED","sponsor":"Asmaa Abdelfattah Elsayed","startDate":"2020-12-01","conditions":"Diabetes Type 2, NAFLD","enrollment":80},{"nctId":"NCT04810156","phase":"PHASE2","title":"Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis","status":"UNKNOWN","sponsor":"Inge Marie Svane","startDate":"2021-04-07","conditions":"Hepatitis, Drug-Induced","enrollment":60},{"nctId":"NCT02823366","phase":"PHASE3","title":"Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid","status":"UNKNOWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2016-01","conditions":"Primary Biliary Cirrhosis","enrollment":104},{"nctId":"NCT05500937","phase":"PHASE2, PHASE3","title":"Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2021-03-01","conditions":"Diabetes Mellitus","enrollment":1000},{"nctId":"NCT01865812","phase":"PHASE2","title":"Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis","status":"COMPLETED","sponsor":"Intercept Pharmaceuticals","startDate":"2013-12-03","conditions":"Primary Biliary Cirrhosis","enrollment":27},{"nctId":"NCT03602560","phase":"PHASE3","title":"ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-10-01","conditions":"Primary Biliary Cholangitis","enrollment":265},{"nctId":"NCT02955602","phase":"PHASE2","title":"Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-11-28","conditions":"Primary Biliary Cirrhosis","enrollment":119},{"nctId":"NCT03226067","phase":"PHASE2","title":"Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.","status":"COMPLETED","sponsor":"Calliditas Therapeutics AB","startDate":"2017-06-26","conditions":"Primary Biliary Cirrhosis","enrollment":111},{"nctId":"NCT04309773","phase":"PHASE3","title":"Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-04-06","conditions":"Primary Sclerosing Cholangitis, Cholestasis","enrollment":104},{"nctId":"NCT02967250","phase":"PHASE1","title":"Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2020-04-01","conditions":"Parkinson Disease","enrollment":5},{"nctId":"NCT03844100","phase":"PHASE1, PHASE2","title":"Effectiveness and Safety in Administrating CNU® Capsule to Refractory Functional Dyspepsia Patients","status":"COMPLETED","sponsor":"Gangnam Severance Hospital","startDate":"2019-11-01","conditions":"Dyspepsia, Biliary Dysplasia","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":69,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["URSO, UDCA"],"phase":"marketed","status":"active","brandName":"Ursodeoxycholic Acid (URSO)","genericName":"Ursodeoxycholic Acid (URSO)","companyName":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","companyId":"cancer-institute-and-hospital-chinese-academy-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ursodeoxycholic acid is a bile acid that reduces cholesterol saturation in bile and promotes its solubilization, while also exerting cytoprotective and anti-inflammatory effects on hepatocytes and biliary epithelium. Used for Primary biliary cholangitis (PBC), Primary sclerosing cholangitis (PSC), Gallstone dissolution.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}